Johnson & Johnson’s Q3 2026 results reflect persistent headwinds in the MedTech segment from Middle East conflict disruptions, European austerity measures, and China pricing pressure, which offset robust Innovative Medicine growth driven by Tremfya and other key products. These factors have shaped trader consensus around an adjusted EPS miss relative to the $2.54 consensus, with revenue also viewed as vulnerable to the same international softness despite pharmaceutical momentum. The market-implied 100% probability for “No” captures this aggregated real-money assessment of near-term fundamentals. Tail risks remain limited but include potential one-time gains, sharper-than-expected Tremfya uptake, or favorable currency moves that could still produce a narrow beat.